Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial.

• Results Overview

  The oral medication upadacitinib showed significant improvement in eczema severity compared to placebo, with higher doses showing better results and an acceptable safety profile.

• Study Summary

  Num Participants:

  167

  Study Type:

  Rct

  Control Group:

  Placebo

  Efficacy End Points Treatment:

  {'EASI % improvement': {'7.5mg': 39, '15mg': 62, '30mg': 74}}

  Efficacy End Points Control:

  {'EASI % improvement': 23}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected